Cargando…

Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan

BACKGROUND: The use of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) decreases the frequency of COPD exacerbations. Recently, pneumonia was reported as a complication of ICS in patients with COPD. However, there have been few reports concerning the relati...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirano, Ryosuke, Fujita, Masaki, Matsumoto, Takemasa, On, Rintaro, Watanabe, Kentaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207395/
https://www.ncbi.nlm.nih.gov/pubmed/30498340
http://dx.doi.org/10.2147/COPD.S180349
_version_ 1783366514919866368
author Hirano, Ryosuke
Fujita, Masaki
Matsumoto, Takemasa
On, Rintaro
Watanabe, Kentaro
author_facet Hirano, Ryosuke
Fujita, Masaki
Matsumoto, Takemasa
On, Rintaro
Watanabe, Kentaro
author_sort Hirano, Ryosuke
collection PubMed
description BACKGROUND: The use of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) decreases the frequency of COPD exacerbations. Recently, pneumonia was reported as a complication of ICS in patients with COPD. However, there have been few reports concerning the relationship between ICS and pneumonia in Japan. Moreover, there is little information on the types of ICS. PATIENTS AND METHODS: To clarify these issues, we investigated the occurrence of pneumonia in Japanese patients with COPD. We retrospectively investigated the occurrence of pneumonia in patients with COPD in our hospital from January 2009 to August 2013. Morbidity and mortality, ICS use, age, sex, and COPD classification were investigated. A group of patients with COPD who received ICS and a group of patients with COPD who did not receive ICS were compared each other. RESULTS: Fifty-one patients developed pneumonia among 639 (7.98%) patients with COPD. Among 252 ICS-treated patients with COPD, 13 (5.16%) developed pneumonia, and among 387 ICS-untreated patients with COPD, 38 (9.82%) developed pneumonia. The mortality rate in ICS-treated patients with COPD was 7.7%, while that in ICS-untreated patients was 10.5% (P=0.767). Fluticasone/salmeterol use tended to show a higher risk of pneumonia than budesonide/formoterol use. The use of ICS did not increase the risk of pneumonia or mortality due to pneumonia in Japanese patients with COPD. CONCLUSION: ICS might not increase the risk of pneumonia in Japanese patients with COPD. In regard to pneumonia, ICS can be safely used in Japanese patients with COPD. Because there are apparent differences in lung diseases among races, appropriate treatment should be investigated in each country.
format Online
Article
Text
id pubmed-6207395
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62073952018-11-29 Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan Hirano, Ryosuke Fujita, Masaki Matsumoto, Takemasa On, Rintaro Watanabe, Kentaro Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: The use of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) decreases the frequency of COPD exacerbations. Recently, pneumonia was reported as a complication of ICS in patients with COPD. However, there have been few reports concerning the relationship between ICS and pneumonia in Japan. Moreover, there is little information on the types of ICS. PATIENTS AND METHODS: To clarify these issues, we investigated the occurrence of pneumonia in Japanese patients with COPD. We retrospectively investigated the occurrence of pneumonia in patients with COPD in our hospital from January 2009 to August 2013. Morbidity and mortality, ICS use, age, sex, and COPD classification were investigated. A group of patients with COPD who received ICS and a group of patients with COPD who did not receive ICS were compared each other. RESULTS: Fifty-one patients developed pneumonia among 639 (7.98%) patients with COPD. Among 252 ICS-treated patients with COPD, 13 (5.16%) developed pneumonia, and among 387 ICS-untreated patients with COPD, 38 (9.82%) developed pneumonia. The mortality rate in ICS-treated patients with COPD was 7.7%, while that in ICS-untreated patients was 10.5% (P=0.767). Fluticasone/salmeterol use tended to show a higher risk of pneumonia than budesonide/formoterol use. The use of ICS did not increase the risk of pneumonia or mortality due to pneumonia in Japanese patients with COPD. CONCLUSION: ICS might not increase the risk of pneumonia in Japanese patients with COPD. In regard to pneumonia, ICS can be safely used in Japanese patients with COPD. Because there are apparent differences in lung diseases among races, appropriate treatment should be investigated in each country. Dove Medical Press 2018-10-23 /pmc/articles/PMC6207395/ /pubmed/30498340 http://dx.doi.org/10.2147/COPD.S180349 Text en © 2018 Hirano et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Hirano, Ryosuke
Fujita, Masaki
Matsumoto, Takemasa
On, Rintaro
Watanabe, Kentaro
Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan
title Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan
title_full Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan
title_fullStr Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan
title_full_unstemmed Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan
title_short Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan
title_sort inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in japan
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207395/
https://www.ncbi.nlm.nih.gov/pubmed/30498340
http://dx.doi.org/10.2147/COPD.S180349
work_keys_str_mv AT hiranoryosuke inhaledcorticosteroidsmightnotincreasetheriskofpneumoniainpatientswithchronicobstructivepulmonarydiseaseinjapan
AT fujitamasaki inhaledcorticosteroidsmightnotincreasetheriskofpneumoniainpatientswithchronicobstructivepulmonarydiseaseinjapan
AT matsumototakemasa inhaledcorticosteroidsmightnotincreasetheriskofpneumoniainpatientswithchronicobstructivepulmonarydiseaseinjapan
AT onrintaro inhaledcorticosteroidsmightnotincreasetheriskofpneumoniainpatientswithchronicobstructivepulmonarydiseaseinjapan
AT watanabekentaro inhaledcorticosteroidsmightnotincreasetheriskofpneumoniainpatientswithchronicobstructivepulmonarydiseaseinjapan